These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35510337)

  • 1. Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis.
    Vasilogianni AM; Al-Majdoub ZM; Achour B; Annie Peters S; Barber J; Rostami-Hodjegan A
    Clin Pharmacol Ther; 2022 Sep; 112(3):699-710. PubMed ID: 35510337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects.
    Vasilogianni AM; Al-Majdoub ZM; Achour B; Peters SA; Rostami-Hodjegan A; Barber J
    Br J Clin Pharmacol; 2022 Feb; 88(4):1811-1823. PubMed ID: 34599518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes.
    Takahashi RH; Forrest WF; Smith AD; Badee J; Qiu N; Schmidt S; Collier AC; Parrott N; Fowler S
    Drug Metab Dispos; 2021 Sep; 49(9):760-769. PubMed ID: 34187837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
    Kong TY; Kwon SS; Cheong JC; Kim HS; Kim JY; Lee HS
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29659506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
    Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes.
    Kong TY; Kim JH; Kwon SS; Cheong JC; Kim HS; In MK; Lee HS
    Arch Pharm Res; 2017 Jun; 40(6):727-735. PubMed ID: 28484907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method.
    Yan T; Gao S; Peng X; Shi J; Xie C; Li Q; Lu L; Wang Y; Zhou F; Liu Z; Hu M
    Pharm Res; 2015 Mar; 32(3):1141-57. PubMed ID: 25288013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics.
    Kiss M; Mbasu R; Nicolaï J; Barnouin K; Kotian A; Mooij MG; Kist N; Wijnen RMH; Ungell AL; Cutler P; Russel FGM; de Wildt SN
    Drug Metab Dispos; 2021 Dec; 49(12):1038-1046. PubMed ID: 34548392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Hepatic Organic Anion Transport Proteins OAT2 and OAT7 in Human Liver Tissue and Primary Hepatocytes.
    Vildhede A; Kimoto E; Rodrigues AD; Varma MVS
    Mol Pharm; 2018 Aug; 15(8):3227-3235. PubMed ID: 29906129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes.
    Achour B; Al Feteisi H; Lanucara F; Rostami-Hodjegan A; Barber J
    Drug Metab Dispos; 2017 Jun; 45(6):666-675. PubMed ID: 28373266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
    Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
    Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.
    Couto N; Al-Majdoub ZM; Gibson S; Davies PJ; Achour B; Harwood MD; Carlson G; Barber J; Rostami-Hodjegan A; Warhurst G
    Drug Metab Dispos; 2020 Apr; 48(4):245-254. PubMed ID: 31959703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics.
    Couto N; Al-Majdoub ZM; Achour B; Wright PC; Rostami-Hodjegan A; Barber J
    Mol Pharm; 2019 Feb; 16(2):632-647. PubMed ID: 30608694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
    Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5'-Diphosphate-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity.
    Achour B; Dantonio A; Niosi M; Novak JJ; Al-Majdoub ZM; Goosen TC; Rostami-Hodjegan A; Barber J
    Drug Metab Dispos; 2018 Jun; 46(6):805-812. PubMed ID: 29581103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related changes in hepatic expression and activity of drug metabolizing enzymes in male wild-type and breast cancer resistance protein knockout mice.
    Zheng H; Wang L; Zeng S; Chen J; Wang H; Yu J; Gong X; Jiang H; Yang X; Qi X; Wang Y; Lu L; Hu M; Zhu L; Liu Z
    Biopharm Drug Dispos; 2018 Jul; 39(7):344-353. PubMed ID: 30016542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.
    Achour B; Dantonio A; Niosi M; Novak JJ; Fallon JK; Barber J; Smith PC; Rostami-Hodjegan A; Goosen TC
    Drug Metab Dispos; 2017 Oct; 45(10):1102-1112. PubMed ID: 28768682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
    El-Khateeb E; Achour B; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Mol Pharm; 2021 Sep; 18(9):3563-3577. PubMed ID: 34428046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate Glucuronosyltransferase.
    Ahmed AN; Rostami-Hodjegan A; Barber J; Al-Majdoub ZM
    Drug Metab Dispos; 2022 Aug; 50(8):1119-1125. PubMed ID: 35636771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
    Knights KM; Rowland A; Miners JO
    Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.